263 studies found for:    PD-1
Show Display Options
Rank Status Study
21 Not yet recruiting A Study to Assess Safety, Tolerability and Preliminary Activity of the Combination of FAK (Defactinib) and PD-1(Pembrolizumab) Inhibition in Patients With Advanced Solid Malignancies
Conditions: Carcinoma, Non-small-cell Lung;   Mesothelioma;   Pancreatic Neoplasms
Interventions: Drug: Defactinib;   Drug: Pembrolizumab
22 Recruiting A Comparison of Continuous Bevacizumab (Avastin) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Participants With Glioblastoma
Condition: Glioblastoma
Interventions: Drug: Bevacizumab;   Drug: Lomustine;   Drug: Placebo;   Radiation: Radiotherapy;   Drug: SOC;   Drug: Temozolomide
23 Not yet recruiting Phase II Study of Pembrolizumab and Ipilimumab Following Initial Anti-PD1/L1 Antibody
Condition: Melanoma
Intervention: Drug: Pembrolizumab and Ipilimumab combination
24 Recruiting A Phase I Study of an Anti-KIR Antibody in Combination With an Anti-PD1 Antibody in Patients With Advanced Solid Tumors
Condition: CANCER,NOS
Interventions: Drug: Lirilumab;   Drug: Nivolumab
25 Recruiting Immune Modulation Study in Patients With Metastatic Melanoma Treated With Anti-PD1 Monoclonal Antibodies
Condition: Metastatic Melanoma
Interventions: Biological: blood sampling;   Drug: Nivolumab
26 Recruiting Neoadjuvant Anti-PD-1, Nivolumab in Resectable NSCLC
Condition: Non-Small Cell Lung Cancer
Intervention: Drug: Nivolumab
27 Active, not recruiting Phase I Biomarker Study (BMS-936558)
Condition: Renal Cell Carcinoma
Intervention: Drug: BMS-936558 (Anti-PD-1)
28 Recruiting Treatment of Advanced Melanoma With MK-3475 and Peginterferon
Condition: Melanoma
Interventions: Drug: MK-3475;   Drug: Peginterferon alfa-2b
29 Completed PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
Condition: Renal Cell Carcinoma
Interventions: Drug: CT-011;   Biological: DC/RCC fusion vaccine
30 Recruiting Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab
Condition: Melanoma
Interventions: Biological: 6MHP;   Drug: Pembrolizumab
31 Recruiting Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission
Conditions: Acute Myelogenous Leukemia;   AML
Interventions: Biological: DC AML Vaccine;   Drug: CT-011
32 Active, not recruiting Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
Condition: Multiple Myeloma
Interventions: Drug: CT-011;   Biological: Dendritic Cell Fusion Vaccine
33 Recruiting Serial [18F]Fluorodeoxyglucose ([18F]FDG )PET/CT as a Biomarker of Therapeutic Response in Anti-PD1/PDL1 Therapy
Condition: Non-small Cell Lung Cancer Starting Anti-PD1/PDL1 Therapy
Intervention: Radiation: [18F]fluoroglucose(FDG)
34 Recruiting Oligomeric Alpha-synuclein in Multiple System Atrophy
Condition: Multiple System Atrophy (MSA)
Intervention:
35 Suspended Gemcitabine and CT-011 for Resected Pancreatic Cancer
Conditions: Pancreatic Neoplasms;   Cancer of the Pancreas;   Neoplasms Pancreatic;   Pancreatic Cancer;   Pancreas Cancer
Interventions: Biological: CT-011;   Drug: Gemcitabine
36 Recruiting Study of Anti-PD-1 Therapy for HPV-associated Recurrent Respiratory Papilloma Patients With Laryngeal, Tracheal and/or Pulmonary Involvement
Condition: Recurrent Respiratory Papillomatosis
Intervention: Drug: Pembrolizumab
37 Not yet recruiting Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant
Condition: Acute Myeloid Leukemia
Interventions: Drug: Fludarabine;   Drug: Melphalan;   Drug: Pembrolizumab
38 Withdrawn Study of the Anti-PD-1 Antibody Nivolumab in Combination With Dabrafenib and/or Trametinib
Condition: Metastatic Melanoma
Interventions: Drug: Nivolumab;   Drug: Trametinib;   Drug: Dabrafenib
39 Recruiting Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies
Conditions: Advanced Cancer;   Advanced Malignancies
Interventions: Drug: REGN2810;   Radiation: Hypofractionated radiotherapy;   Drug: Cyclophosphamide;   Drug: Docetaxel;   Drug: Carboplatin;   Drug: GM-CSF
40 Not yet recruiting A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural Mesothelioma
Condition: Pleural Mesothelioma
Interventions: Drug: Pembrolizumab;   Drug: Cisplatin and Pemetrexed

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years